Navigation Menu

Clinical Trial External Search


Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Kevin L. Rakszawski, MD

Kevin L. Rakszawski, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Disease Teams:
Cancer Institute, Bone Marrow Transplantation Team
Cancer Institute, Leukemia and Lymphoma Team
KLR307@psu.edu

Research Interests

Dr. Kevin Rakszawski's research interests include end-of-life care in patients with hematologic malignancies; lymphoma therapeutics; and prevention and treatment of complications of blood and marrow transplantation.

  • Transplants
  • Therapeutics
  • T-Lymphocytes
  • Stem Cells
  • Acute Myeloid Leukemia
  • Allogeneic Cells
  • Cyclophosphamide
  • Survival
  • Tissue Donors
  • Systematic Reviews
  • Hematopoietic Stem Cells
  • Cohort Studies

Clinical Trials

A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting
Phase III study of daratumumab/rHuPH20 (NSC- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC Study)
A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)

Recent Publications

2024

Naik, S, Rakszawski, K, Zheng, H, Claxton, D, Minagawa, K & Mineishi, S 2024, 'Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia', International journal of molecular sciences, vol. 25, no. 2, 957. https://doi.org/10.3390/ijms25020957
Guare, EG, Hale, CM, Sivik, J, Lehman, E, Inoue, Y, Rakszawski, K, Songdej, N, Nickolich, M, Zheng, H, Naik, S, Claxton, D, Rybka, W, Hohl, R, Mineishi, S, Minagawa, K & Paules, CI 2024, 'The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma', Transplant Infectious Disease, vol. 26, no. 2, e14241. https://doi.org/10.1111/tid.14241

2023

Zhou, H, Jia, B, Annageldiyev, C, Minagawa, K, Zhao, C, Mineishi, S, Ehmann, WC, Naik, SG, Cioccio, J, Wirk, B, Songdej, N, Rakszawski, KL, Nickolich, MS, Shen, J & Zheng, H 2023, 'CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia', Frontiers in immunology, vol. 14, 1169144. https://doi.org/10.3389/fimmu.2023.1169144
Potiaumpai, M, Schmitz, KH, Mineishi, S, Naik, S, Wirk, B, Rakszawski, K, Ehmann, WC, Claxton, D, Nickolich, M, Zemel, BS & Zheng, H 2023, 'IMPROVE-BMT: A protocol for a pilot randomised controlled trial of prehabilitation exercise for adult haematopoietic stem cell transplant recipients', BMJ open, vol. 13, no. 1, e066841. https://doi.org/10.1136/bmjopen-2022-066841

2022

Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Shah, N, Tuanquin, L, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Shike, H 2023, 'Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis', Annals of Hematology, vol. 102, no. 3, pp. 613-620. https://doi.org/10.1007/s00277-022-05077-2
Shah, N, Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Mierski, J, Zhou, S, Shike, H, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Tuanquin, L 2022, 'Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide', Leukemia Research, vol. 123, 106969. https://doi.org/10.1016/j.leukres.2022.106969
Pizzola, CJ, Cioccio, J, Rakszawski, KL, Nickolich, M, Ehmann, WC, Rybka, WB, Wirk, B, Naik, S, Zheng, H, Silar, B, Shike, H, Zhou, S, Mineishi, S, Minagawa, K & Claxton, DF 2022, 'Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities', Bone Marrow Transplantation, vol. 57, no. 11, pp. 1743-1745. https://doi.org/10.1038/s41409-022-01821-4
Olecki, EJ, Rakszawski, KL & Peng, JS 2022, 'Pancreatoduodenectomy for monomorphic epitheliotropic intestinal T-cell lymphoma with duodenal obstruction', BMJ case reports, vol. 15, no. 3, e248948. https://doi.org/10.1136/bcr-2022-248948
Zhao, C, Bartock, M, Jia, B, Shah, N, Claxton, DF, Wirk, B, Rakszawski, KL, Nickolich, MS, Naik, SG, Rybka, WB, Ehmann, WCC, Hohl, RJ, Valentin, J, Bernas-Peterson, M, Gerber, EM, Zimmerman, M, Mierski, JA, Mineishi, S & Zheng, H 2022, 'Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant', Journal of Hematology and Oncology, vol. 15, no. 1, 64. https://doi.org/10.1186/s13045-022-01287-3

2021

Herrera, AF, Ahn, KW, Litovich, C, Chen, Y, Assal, A, Bashir, Q, Bayer, RL, Coleman, M, DeFilipp, Z, Farhadfar, N, Greenwood, M, Hahn, T, Horwitz, M, Jacobson, C, Jaglowski, S, Lachance, S, Langston, A, Mattar, B, Maziarz, RT, McGuirk, J, Mian, MAH, Nathan, S, Phillips, A, Rakszawski, K, Sengeloev, H, Shenoy, S, Stuart, R, Sauter, CS, Kharfan-Dabaja, MA & Hamadani, M 2021, 'Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndrome', Blood Advances, vol. 5, no. 18, pp. 3528-3539. https://doi.org/10.1182/bloodadvances.2021004865
Shah, N, Rakszawski, K, Nickolich, M, Ehmann, C, Wirk, B, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Mackey, G, Greiner, R, Brown, V, Claxton, D, Mineishi, S & Minagawa, K 2021, 'Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion', Annals of Hematology, vol. 100, no. 10, pp. 2585-2592. https://doi.org/10.1007/s00277-021-04616-7
Nine-I investigators 2021, 'Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study', The Lancet Haematology, vol. 8, no. 5, pp. e355-e364. https://doi.org/10.1016/S2352-3026(21)00060-0

2020

Van de Louw, A, Twomey, K, Habecker, N & Rakszawski, K 2021, 'Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study', Annals of Hematology, vol. 100, no. 1, pp. 229-237. https://doi.org/10.1007/s00277-020-04197-x